Spironolattone per Alopecia androgenetica

References

1. [1] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
2. [2] Jair Alejandro Valdez-Zertuche et al.. Expert Opin Drug Metab Toxicol. 2025. Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. doi:10.1080/17425255.2025.2461483 PubMed
3. [3] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
4. [4] Aditya K Gupta et al.. PLoS One. 2025. Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. doi:10.1371/journal.pone.0319040 PubMed
5. [5] Sarah Schaffer et al.. Cureus. 2025. A Scoping Review of Exosome Delivery Applications in Hair Loss. doi:10.7759/cureus.81152 PubMed
6. [6] Michael Wang et al.. J Clin Sleep Med. 2025. Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. doi:10.5664/jcsm.11324 PubMed
7. [7] Ping Xue et al.. J Cosmet Dermatol. 2025. A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation for Patients With Androgenetic Alopecia. doi:10.1111/jocd.16665 PubMed
8. [8] Pimpakarn Werachattawatchai et al.. Int J Womens Dermatol. 2025. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … doi:10.1097/JW9.0000000000000227 PubMed
9. [9] Tyan Shin Lee et al.. J Am Acad Dermatol. 2025. An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia. doi:10.1016/j.jaad.2025.02.002 PubMed
10. [10] Paola Loli et al.. Endocrine. 2025. Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment. doi:10.1007/s12020-025-04341-5 PubMed
11. [11] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
12. [12] Nghiem H Nguyen et al.. J Plast Reconstr Aesthet Surg. 2025. Estrogen hormone therapy stabilizes lateral hairline in transfeminine patients: Implications for facial feminization surgery. doi:10.1016/j.bjps.2024.07.044 PubMed
13. [13] Alpana Mohta et al.. Int J Trichology. 2025. Evaluating the Role of the Gabrin Sign in Predicting COVID-19 Severity Among Patients with Androgenic Alopecia. doi:10.4103/ijt.ijt_5_23 PubMed
14. [14] Barbara Owecka et al.. Biomedicines. 2024. The Hormonal Background of Hair Loss in Non-Scarring Alopecias. doi:10.3390/biomedicines12030513 PubMed
15. [15] Afsaneh Sadeghzadeh Bazargan et al.. J Cosmet Dermatol. 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … doi:10.1111/jocd.15979 PubMed
16. [16] Amanda Rosenthal et al.. J Cosmet Laser Ther. 2024. Management of androgenic alopecia: a systematic review of the literature. doi:10.1080/14764172.2024.2362126 PubMed
17. [17] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
18. [18] Mengxue He et al.. Mol Nutr Food Res. 2024. Cannabidiol (CBD) Inhibits Foam Cell Formation via Regulating Cholesterol Homeostasis and Lipid Metabolism. doi:10.1002/mnfr.202400154 PubMed
19. [19] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
20. [20] Ambika Nohria et al.. JAAD Int. 2024. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … doi:10.1016/j.jdin.2024.07.023 PubMed
21. [21] Faiz-Ul Hassan et al.. Front Immunol. 2023. Potential of dietary hemp and cannabinoids to modulate immune response to enhance health and performance in animals: opportunities and challenges. doi:10.3389/fimmu.2023.1285052 PubMed
22. [22] Sincengile Ntshingila et al.. JAAD Int. 2023. Androgenetic alopecia: An update. doi:10.1016/j.jdin.2023.07.005 PubMed
23. [23] Michael Kaiser et al.. Clin Cosmet Investig Dermatol. 2023. Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. doi:10.2147/CCID.S385861 PubMed
24. [24] Chaofan Wang et al.. Clin Cosmet Investig Dermatol. 2023. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. doi:10.2147/CCID.S398950 PubMed
25. [25] Julia L Gao et al.. J Am Acad Dermatol. 2023. Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. doi:10.1016/j.jaad.2021.08.067 PubMed
26. [26] Nathalie Y Ly et al.. J Am Acad Dermatol. 2023. Medical and procedural treatment of androgenetic alopecia - Where are we? doi:10.1016/j.jaad.2023.05.004 PubMed
27. [27] Majed Aleissa. Cureus. 2023. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. doi:10.7759/cureus.43559 PubMed
28. [28] JaBreia F James et al.. J Am Acad Dermatol. 2022. Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review. doi:10.1016/j.jaad.2021.07.048 PubMed
29. [29] Xuelei Liang et al.. Front Med (Lausanne). 2022. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … doi:10.3389/fmed.2022.905140 PubMed
30. [30] Pravesh Sharma et al.. PEC Innov. 2022. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … doi:10.1016/j.pecinn.2022.100044 PubMed
31. [31] Fan Zhang et al.. Clin Cosmet Investig Dermatol. 2022. Observation on the Efficacy of a Combined Treatment for Moderate and Severe Androgenetic Alopecia Incorporating Electric Microneedles. doi:10.2147/CCID.S383289 PubMed
32. [32] Shafik Boyaji et al.. Curr Pain Headache Rep. 2020. The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. doi:10.1007/s11916-020-0835-4 PubMed
33. [33] Chapman Wei et al.. J Am Acad Dermatol. 2020. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. doi:10.1016/j.jaad.2020.05.081 PubMed
34. [34] Solmaz Asnaashari et al.. Altern Ther Health Med. 2020. Herbal Medicines For Treatment of Androgenic Alopecia. PubMed
35. [35] Enrico Carmina et al.. J Clin Endocrinol Metab. 2019. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. doi:10.1210/jc.2018-02548 PubMed
36. [36] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
37. [37] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
38. [38] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
39. [39] G Fabbrocini et al.. Int J Womens Dermatol. 2018. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. doi:10.1016/j.ijwd.2018.05.001 PubMed
40. [40] C Pindado-Ortega et al.. Actas Dermosifiliogr (Engl Ed). 2018. Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. doi:10.1016/j.ad.2018.02.006 PubMed
41. [41] Marlene Rodrigues et al.. BMJ Case Rep. 2017. Androgenic alopecia: an entity to consider in adolescence. doi:10.1136/bcr-2017-220679 PubMed
42. [42] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
43. [43] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
44. [44] Timothy H Schmidt et al.. J Am Acad Dermatol. 2015. Evidence-based approach to cutaneous hyperandrogenism in women. doi:10.1016/j.jaad.2015.05.026 PubMed
45. [45] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
46. [46] Rehab Nabil Shamma et al.. Int J Nanomedicine. 2014. Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. doi:10.2147/IJN.S73010 PubMed
47. [47] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
48. [48] R Sinclair et al.. Br J Dermatol. 2011. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. doi:10.1111/j.1365-2133.2011.10630.x PubMed
49. [49] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
50. [50] Andreas D Katsambas et al.. Clin Dermatol. 2010. Hormonal therapy for acne: why not as first line therapy? facts and controversies. doi:10.1016/j.clindermatol.2009.03.006 PubMed
51. [51] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
52. [52] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
53. [53] Carlijn Hoedemaker et al.. Australas J Dermatol. 2007. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. doi:10.1111/j.1440-0960.2007.00332.x PubMed
54. [54] Serge Ahouansou et al.. Eur J Dermatol. 2007. Association of androgenetic alopecia and hypertension. doi:10.1684/ejd.2007.0152 PubMed
55. [55] V del Marmol et al.. Rev Med Brux. 2004. [Androgenetic alopecia]. PubMed
56. [56] J McMurray et al.. Eur J Heart Fail. 2001. Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. doi:10.1016/s1388-9842(01)00173-8 PubMed
57. [57] E Diamanti-Kandarakis. Curr Pharm Des. 1999. Current aspects of antiandrogen therapy in women. PubMed
58. [58] A Tosti et al.. J Eur Acad Dermatol Venereol. 1999. Management of androgenetic alopecia. PubMed
59. [59] J Shapiro et al.. Dermatol Clin. 1998. Hair regrowth. Therapeutic agents. doi:10.1016/s0733-8635(05)70017-6 PubMed
60. [60] D A Adamopoulos et al.. Clin Endocrinol (Oxf). 1997. Beneficial effect of spironolactone on androgenic alopecia. doi:10.1046/j.1365-2265.1997.3761162.x PubMed
61. [61] G P Redmond et al.. J Am Acad Dermatol. 1990. Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. doi:10.1016/0190-9622(90)70014-9 PubMed
62. [62] B M Burke et al.. Br J Dermatol. 1985. Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. doi:10.1111/j.1365-2133.1985.tb02305.x PubMed